Chronic Kidney Disease

Although the Center for Medicare and Medicaid Innovation (CMMI) has delayed the start of payment models for kidney care, one dialysis provider says it remains committed to the concept.

Last year, a data monitoring committee halted the DAPA-CKD trial when it found the evidence of efficacy was overwhelming, after it was shown the trial met all its primary and secondary end points for patients with chronic kidney disease, with and without type 2 diabetes.

New research highlights a relationship between chronic kidney disease (CKD) and cerebral small vessel disease.

Quality of life is similar between patients with chronic kidney disease (CKD) undergoing hemodialysis and those having continuous ambulatory peritoneal dialysis (CAPD) in the hospital.

Study results indicate a possible relationship between diabetic kidney disease (DKD) and frailty and risk of subsequent delirium and cognitive impairment.

The findings illustrate the importance of prioritizing COVID-19 vaccinations for patients on dialysis.

Anemia, which occurs in over 50% of patients with end-stage kidney disease, should not be considered an obstacle to home dialysis, according to a new report.

The announcement allowing the administration of COVID-19 vaccines in dialysis centers is part of a larger $10 billion investment, largely funded by the American Rescue Plan, to expand access.

Patient data about emergency department use by this population is limited, the authors said.

Improved understanding of the early mechanisms of chronic kidney disease (CKD) may be the next step in efforts to delay or reverse disease progression.

The study examined the cost to Medicare when patients with end-stage renal disease switched from their employer-based health insurance to Medicare between 2007 and 2017 before the end of the 30-month coordination period.

The study, published on World Kidney Day, is the first to report the optimal amount of activity in patients with chronic kidney disease, according to the authors.

More than a year into the COVID-19 pandemic, a new study suggests that individuals recovering from acute kidney injury stemming from COVID-19 will require kidney monitoring after they leave the hospital.

A retrospective study looking at pediatric patients hospitalized in 4 New York hospitals in 2020 with COVID-19 or multisystem inflammatory syndrome in children (MIS-C) found that acute kidney injury (AKI) occurred in 11.8% of patients.

Despite benefitting from organ transplants similarly to other patients with kidney failure, a new study found patients with kidney failure associated with sickle cell disease (SCD) are less likely to receive transplants.

Cutting-edge genetic tools diagnosed 83% of Irish patients with polycystic kidney disease (PKD), identified 36 novel variants, and discovered that seemingly unrelated individuals with the same variant likely inherited it from a common ancestor.

Adherence to guidelines for slowing chronic kidney disease is low, with substantial variation among the United States and other countries.

Older patients are at greater risk of death in the earliest stages of dialysis, while females possibly are at a higher risk than men, a review of studies found.

Patients with chronic kidney disease (CKD) healthy enough not to have seen a specialist have higher hospitalization rates than the general population, according to a recent study.

Planning and education can help create systemwide change in order to implement greater use of advance care planning and palliative care for those with end-stage renal disease (ESRD).

Brandi Riddle, chief financial officer at Strive Health, discussed the role technology and predictive analytics will play in changing kidney care in the future.

Noting each of their benefits, the researchers also caution that to better characterize their safety and efficacy, there’s a need for further investigation among larger patient pools.

Data from nearly 3000 patients across multiple countries with the disease showed that undertreatment was most notable among patient with hemoglobin (Hb) <10 g/dL.

Nephrologist Mary Dittrich, MD, the chief medical officer and executive vice president of U.S. Renal Care as well as cofounder and partner of Boise Kidney & Hypertension Institute, discusses how to keep patients safe while providing high-quality kidney care during the coronavirus disease 2019 pandemic.

A population-based study from the Netherlands showed that individuals with had at least 1 direct relative affected with chronic kidney disease (CKD), suggesting that biomarkers for CKD can aid in detecting the early stages of the disease.

The FDA decision on dapaglifozin for CKD is expected in the second quarter of 2021.

A new study from Sweden cautions against routine discontinuation of renin-angiotensin system (RAS) inhibitors in patients with chronic kidney disease (CKD).

Slowing progression of chronic kidney disease can help mitigate adverse outcomes in minority populations, said Guofen Yan, PhD, associate professor of biostatistics in the Department of Public Health Sciences at the University of Virginia School of Medicine.

This approach allows clinicians to keep using existing prediction models and incorporate chronic kidney disease (CKD) data seamlessly to calibrate patients' risks, said Kunihiro Matsushita, MD, an associate professor in the Department of Epidemiology and Division of Cardiology at Johns Hopkins University.

Two story lines predominated renal news in 2020: coronavirus disease 2019's effect on the kidneys and the overwhelming benefits of sodium-glucose cotransporter 2 inhibitors for those with chronic kidney disease and type 2 diabetes.